Sheaff Brock Investment Advisors LLC decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.6% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,678 shares of the company’s stock after selling 398 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in IDEXX Laboratories were worth $883,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. WMS Partners LLC grew its holdings in shares of IDEXX Laboratories by 0.3% in the second quarter. WMS Partners LLC now owns 1,583 shares of the company’s stock worth $256,000 after purchasing an additional 4 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in shares of IDEXX Laboratories by 0.3% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,547 shares of the company’s stock worth $1,057,000 after purchasing an additional 19 shares during the last quarter. Strs Ohio grew its holdings in shares of IDEXX Laboratories by 0.7% in the second quarter. Strs Ohio now owns 5,929 shares of the company’s stock worth $957,000 after purchasing an additional 41 shares during the last quarter. National Asset Management Inc. grew its holdings in shares of IDEXX Laboratories by 2.1% in the second quarter. National Asset Management Inc. now owns 2,051 shares of the company’s stock worth $332,000 after purchasing an additional 42 shares during the last quarter. Finally, Advisor Group Inc. grew its holdings in shares of IDEXX Laboratories by 1.1% in the second quarter. Advisor Group Inc. now owns 4,998 shares of the company’s stock worth $732,000 after purchasing an additional 52 shares during the last quarter. Institutional investors and hedge funds own 86.80% of the company’s stock.

A number of research analysts have recently commented on IDXX shares. Canaccord Genuity restated a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a report on Friday, October 6th. Bank of America upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target on the stock in a report on Wednesday, August 23rd. Stifel Nicolaus restated a “buy” rating and issued a $185.00 price target on shares of IDEXX Laboratories in a report on Monday, August 21st. Finally, Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price target on the stock in a report on Tuesday, October 24th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $173.67.

In related news, Chairman Jonathan W. Ayers sold 54,000 shares of the company’s stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $151.32, for a total value of $8,171,280.00. Following the completion of the sale, the chairman now directly owns 1,064,573 shares of the company’s stock, valued at $161,091,186.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Giovani Twigge sold 2,000 shares of the stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $156.07, for a total transaction of $312,140.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 110,000 shares of company stock valued at $16,686,200. 2.77% of the stock is owned by insiders.

Shares of IDEXX Laboratories, Inc. (IDXX) opened at $159.30 on Tuesday. IDEXX Laboratories, Inc. has a one year low of $113.71 and a one year high of $173.01. The firm has a market cap of $13,518.90, a PE ratio of 52.19, a P/E/G ratio of 2.34 and a beta of 0.42. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The company had revenue of $492.00 million during the quarter, compared to analyst estimates of $492.94 million. During the same period in the prior year, the firm earned $0.62 earnings per share. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. analysts anticipate that IDEXX Laboratories, Inc. will post 3.24 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Sheaff Brock Investment Advisors LLC Has $883,000 Holdings in IDEXX Laboratories, Inc. (IDXX)” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://theolympiareport.com/2017/12/05/sheaff-brock-investment-advisors-llc-has-883000-holdings-in-idexx-laboratories-inc-idxx.html.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.